Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis

Novartis has entered into a collaboration with Pear Therapeutics to develop novel prescription digital therapeutics, software applications designed to effectively treat disease and improve clinical outcomes for patients. The collaboration brings together Novartis expertise in biomedical research and clinical development with Pear’s leading experience in digital therapeutics design and implementation. http://www.worldpharmanews.com/novartis/4311-novartis-and-pear-therapeutics-to-develop-digital-therapeutics-for-patients-with-schizophrenia-and-multiple-sclerosis